GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LENZ Therapeutics Inc (NAS:LENZ) » Definitions » Tax Provision

LENZ (LENZ Therapeutics) Tax Provision : $-0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is LENZ Therapeutics Tax Provision?

LENZ Therapeutics's tax provision for the three months ended in Dec. 2024 was $-0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.00 Mil.


LENZ Therapeutics Tax Provision Historical Data

The historical data trend for LENZ Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENZ Therapeutics Tax Provision Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Tax Provision
- -0.35 0.18 -

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LENZ Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LENZ Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.